Mersana Therapeutics (MRSN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

MRSN Stock Forecast


Mersana Therapeutics stock forecast is as follows: an average price target of $3.00 (represents a 35.14% upside from MRSN’s last price of $2.22) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

MRSN Price Target


The average price target for Mersana Therapeutics (MRSN) is $3.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 35.14% upside from MRSN's last price of $2.22.

MRSN Analyst Ratings


Buy

According to 5 Wall Street analysts, Mersana Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MRSN stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Mersana Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 14, 2024Collen KusyRobert W. Baird$3.00$1.35122.22%35.14%
Row per page
Go to

The latest Mersana Therapeutics stock forecast, released on Aug 14, 2024 by Collen Kusy from Robert W. Baird, set a price target of $3.00, which represents a 122.22% increase from the stock price at the time of the forecast ($1.35), and a 35.14% increase from MRSN last price ($2.22).

Mersana Therapeutics Price Target by Period


1M3M12M
# Anlaysts--1
Avg Price Target--$3.00
Last Closing Price$2.22$2.22$2.22
Upside/Downside-100.00%-100.00%35.14%

In the current month, the average price target of Mersana Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Mersana Therapeutics's last price of $2.22. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Nov 15, 2024CitigroupBuyBuyInitialise
Feb 29, 2024GuggenheimUnderperformUnderperformHold
Feb 29, 2024WedbushBuyBuyHold
Feb 29, 2024Wedbush-OutperformUpgrade
Feb 28, 2024BTIG-BuyUpgrade
Dec 04, 2023Citigroup-BuyUpgrade
Jul 27, 2023Piper Sandler-OverweightInitialise
Jul 27, 2023Scotiabank-Sector OutperformInitialise
Jun 15, 2023Guggenheim-BuyInitialise
Feb 18, 2022SVB LeerinkOutperformOutperformHold
Row per page
Go to

Mersana Therapeutics's last stock rating was published by Citigroup on Nov 15, 2024. The company gave MRSN a "Buy" rating, the same as its previous rate.

Mersana Therapeutics Financial Forecast


Mersana Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$10.70M-$10.65M$7.80M$14.69M$5.57M$4.28M$2.04M$11.00K$11.00K$11.00K$11.00K$11.00K$11.00K$796.00K$11.00K$42.00K$844.00K
Avg Forecast$9.08M$9.42M$9.76M$10.13M$6.09M$6.05M$6.01M$5.90M$7.64M$7.53M$8.72M$8.50M$14.74M$9.60M$12.93M$14.00M$15.28M$56.78M$2.20M$17.24M$5.33K$120.50K$170.00K$312.80K$202.20K$439.20K$306.00K$390.67K$583.33K$350.00K
High Forecast$13.86M$14.37M$14.90M$15.45M$9.30M$9.24M$9.18M$9.00M$15.40M$11.49M$8.72M$12.97M$29.54M$9.75M$19.73M$21.36M$23.32M$56.78M$2.20M$17.24M$5.33K$120.50K$170.00K$312.80K$202.20K$439.20K$306.00K$390.67K$583.33K$350.00K
Low Forecast$3.67M$3.81M$3.95M$4.10M$2.47M$2.45M$2.43M$2.39M$1.44M$3.05M$8.72M$3.44M$7.12M$9.45M$5.23M$5.66M$6.18M$56.78M$2.20M$17.24M$5.33K$120.50K$170.00K$312.80K$202.20K$439.20K$306.00K$390.67K$583.33K$350.00K
# Analysts111111127333633344443333999988
Surprise %------------0.73%-0.82%0.56%0.96%0.10%1.95%0.12%2.06%0.09%0.06%0.04%0.05%0.03%2.60%0.03%0.07%2.41%

Mersana Therapeutics's average Quarter revenue forecast for Mar 24 based on 3 analysts is $8.50M, with a low forecast of $3.44M, and a high forecast of $12.97M. MRSN's average Quarter revenue forecast represents a -20.54% decrease compared to the company's last Quarter revenue of $10.70M (Dec 23).

Mersana Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111127333633344443333999988
EBITDA------------$-19.00M-$-54.31M$-54.86M$-45.83M$-59.64M$-51.23M$-46.33M$-47.79M$-45.16M$-40.61M$-34.37M$-28.49M$-22.14M$-19.45M$-16.59M$-15.88M$-16.38M
Avg Forecast$-8.42M$-8.73M$-9.05M$-9.39M$-5.65M$-5.61M$-5.58M$-5.47M$-7.08M$-6.98M$-8.08M$-34.46M$-13.66M$-8.90M$-11.98M$-36.85M$-44.02M$-52.97M$-2.05M$-39.41M$-4.97K$-112.40K$-158.58K$-24.68M$-188.62K$-409.69K$-285.44K$-17.49M$-544.14K$-326.49K
High Forecast$-3.41M$-3.53M$-3.66M$-3.80M$-2.29M$-2.27M$-2.26M$-2.21M$-1.33M$-2.82M$-8.08M$-27.56M$-6.60M$-8.76M$-4.85M$-29.48M$-35.21M$-52.97M$-2.05M$-31.53M$-4.97K$-112.40K$-158.58K$-19.74M$-188.62K$-409.69K$-285.44K$-13.99M$-544.14K$-326.49K
Low Forecast$-12.84M$-13.32M$-13.81M$-14.32M$-8.62M$-8.56M$-8.51M$-8.34M$-14.27M$-10.65M$-8.08M$-41.35M$-27.38M$-9.04M$-18.29M$-44.22M$-52.82M$-52.97M$-2.05M$-47.30M$-4.97K$-112.40K$-158.58K$-29.61M$-188.62K$-409.69K$-285.44K$-20.98M$-544.14K$-326.49K
Surprise %------------1.39%-4.53%1.49%1.04%1.13%24.94%1.18%9608.16%401.77%256.10%1.39%151.05%54.04%68.15%0.95%29.18%50.16%

undefined analysts predict MRSN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Mersana Therapeutics's previous annual EBITDA (undefined) of $NaN.

Mersana Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111127333633344443333999988
Net Income------------$-18.56M-$-54.31M$-57.15M$-45.89M$-60.69M$-52.98M$-47.98M$-49.96M$-45.47M$-40.91M$-34.69M$-28.84M$-22.49M$-19.79M$-16.93M$-16.25M$-16.79M
Avg Forecast$-21.06M$-20.67M$-20.65M$-22.65M$-21.84M$-22.58M$-22.83M$-23.56M$-18.36M$-21.07M$-20.46M$-35.15M$-19.66M$-43.91M$-53.56M$-37.59M$-45.12M$484.61K$-61.84M$-40.20M$-79.79M$-69.01M$-59.09M$-24.91M$-38.68M$-37.03M$-35.42M$-17.84M$-46.34M$-45.33M
High Forecast$-4.76M$-4.67M$-4.67M$-5.12M$-4.94M$-5.10M$-5.16M$-5.33M$-12.96M$-4.76M$-4.63M$-28.12M$-13.76M$-9.92M$-12.10M$-30.07M$-36.09M$484.61K$-61.84M$-32.16M$-79.79M$-69.01M$-59.09M$-19.93M$-38.68M$-37.03M$-35.42M$-14.27M$-46.34M$-45.33M
Low Forecast$-35.46M$-34.80M$-34.78M$-38.15M$-36.78M$-38.02M$-38.44M$-39.67M$-22.68M$-35.47M$-34.46M$-42.18M$-25.55M$-73.94M$-90.18M$-45.11M$-54.14M$484.61K$-61.84M$-48.24M$-79.79M$-69.01M$-59.09M$-29.89M$-38.68M$-37.03M$-35.42M$-21.41M$-46.34M$-45.33M
Surprise %------------0.94%-1.01%1.52%1.02%-125.24%0.86%1.19%0.63%0.66%0.69%1.39%0.75%0.61%0.56%0.95%0.35%0.37%

Mersana Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MRSN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Mersana Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111127333633344443333999988
SG&A------------$10.13M-$18.19M$18.33M$14.80M$14.57M$14.80M$12.78M$10.67M$10.12M$8.88M$7.21M$5.91M$5.88M$5.17M$4.94M$4.21M$4.44M
Avg Forecast$1.61B$1.67B$1.74B$1.80B$1.08B$1.08B$1.07B$1.05B$1.36B$1.34B$1.55B$1.51B$2.62B$1.71B$2.30B$10.17M$9.83M$10.09B$391.27M$10.87M$947.61K$21.41M$30.21M$55.58M$35.93M$78.04M$54.37M$69.42M$103.65M$62.19M
High Forecast$2.46B$2.55B$2.65B$2.75B$1.65B$1.64B$1.63B$1.60B$2.74B$2.04B$1.55B$2.31B$5.25B$1.73B$3.51B$12.20M$11.80M$10.09B$391.27M$13.05M$947.61K$21.41M$30.21M$55.58M$35.93M$78.04M$54.37M$69.42M$103.65M$62.19M
Low Forecast$652.80M$677.00M$702.09M$728.11M$438.10M$435.28M$432.48M$424.04M$255.70M$541.26M$1.55B$611.33M$1.26B$1.68B$929.67M$8.13M$7.86M$10.09B$391.27M$8.70M$947.61K$21.41M$30.21M$55.58M$35.93M$78.04M$54.37M$69.42M$103.65M$62.19M
Surprise %------------0.00%-0.01%1.80%1.51%0.00%0.04%1.18%11.26%0.47%0.29%0.13%0.16%0.08%0.10%0.07%0.04%0.07%

Mersana Therapeutics's average Quarter SG&A projection for Mar 24 is $1.51B, based on 3 Wall Street analysts, with a range of $611.33M to $2.31B. The forecast indicates a 14808.84% rise compared to MRSN last annual SG&A of $10.13M (Dec 23).

Mersana Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts111111127333633344443333999988
EPS------------$-0.13-$-0.47$-0.53$-0.45$-0.62$-0.55$-0.60$-0.69$-0.63$-0.59$-0.50$-0.42$-0.33$-0.33$-0.35$-0.34$-0.35
Avg Forecast$-0.17$-0.17$-0.17$-0.18$-0.18$-0.18$-0.19$-0.19$-0.15$-0.17$-0.17$-0.18$-0.16$-0.36$-0.44$-0.43$-0.49-$-0.51$-0.31$-0.66$-0.57$-0.49$-0.39$-0.32$-0.30$-0.29$-0.37$-0.38$-0.37
High Forecast$-0.04$-0.04$-0.04$-0.04$-0.04$-0.04$-0.04$-0.04$-0.11$-0.04$-0.04$-0.04$-0.11$-0.08$-0.10$-0.10$-0.11-$-0.51$-0.31$-0.66$-0.57$-0.49$-0.39$-0.32$-0.30$-0.29$-0.37$-0.38$-0.37
Low Forecast$-0.29$-0.28$-0.28$-0.31$-0.30$-0.31$-0.31$-0.32$-0.18$-0.29$-0.28$-0.30$-0.21$-0.60$-0.73$-0.72$-0.83-$-0.51$-0.31$-0.66$-0.57$-0.49$-0.39$-0.32$-0.30$-0.29$-0.37$-0.38$-0.37
Surprise %------------0.81%-1.08%1.24%0.91%-155.35%1.08%1.94%1.05%1.11%1.21%1.27%1.32%1.08%1.13%0.95%0.89%0.94%

According to undefined Wall Street analysts, Mersana Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MRSN previous annual EPS of $NaN (undefined).

Mersana Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals$0.34$3.67979.41%Buy
INZYInozyme Pharma$2.79$14.67425.81%Buy
RLAYRelay Therapeutics$4.66$19.40316.31%Buy
PLRXPliant Therapeutics$12.73$39.71211.94%Buy
ABOSAcumen Pharmaceuticals$2.37$7.00195.36%Buy
DAWNDay One Biopharmaceuticals$13.62$38.80184.88%Buy
TERNTerns Pharmaceuticals$5.60$14.25154.46%Buy
CGEMCullinan Oncology$12.58$31.50150.40%Buy
RCUSArcus Biosciences$14.62$33.00125.72%Buy
REPLReplimune Group$11.23$24.20115.49%Buy
SNDXSyndax Pharmaceuticals$15.95$34.30115.05%Buy
VRDNViridian Therapeutics$19.79$37.9291.61%Buy
MRUSMerus$42.93$77.1379.66%Buy
KURAKura Oncology$15.91$26.0063.42%Buy
MRSNMersana Therapeutics$2.22$3.0035.14%Buy
AMLXAmylyx Pharmaceuticals$5.23$6.6727.53%Buy
PTGXProtagonist Therapeutics$40.65$50.0023.00%Buy
HOOKHOOKIPA Pharma$2.72$3.0010.29%Buy
RVMDRevolution Medicines, Inc. Warrant$57.07$60.636.24%Buy
CERECerevel Therapeutics$44.96$33.50-25.49%Buy

MRSN Forecast FAQ


Is Mersana Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, Mersana Therapeutics (MRSN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of MRSN's total ratings.

What is MRSN's price target?

Mersana Therapeutics (MRSN) average price target is $3 with a range of $3 to $3, implying a 35.14% from its last price of $2.22. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Mersana Therapeutics stock go up soon?

According to Wall Street analysts' prediction for MRSN stock, the company can go up by 35.14% (from the last price of $2.22 to the average price target of $3), up by 35.14% based on the highest stock price target, and up by 35.14% based on the lowest stock price target.

Can Mersana Therapeutics stock reach $3?

MRSN's average twelve months analyst stock price target of $3 does not support the claim that Mersana Therapeutics can reach $3 in the near future.

What are Mersana Therapeutics's analysts' financial forecasts?

Mersana Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $24.06M (high $36.72M, low $9.74M), average EBITDA is $-22.301M (high $-9.024M, low $-34.032M), average net income is $-90.814M (high $-20.525M, low $-153M), average SG&A $4.28B (high $6.52B, low $1.73B), and average EPS is $-0.74 (high $-0.167, low $-1.246). MRSN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $38.39M (high $58.58M, low $15.53M), average EBITDA is $-35.581M (high $-14.397M, low $-54.297M), average net income is $-85.034M (high $-19.219M, low $-143M), average SG&A $6.82B (high $10.41B, low $2.76B), and average EPS is $-0.693 (high $-0.157, low $-1.167).

Did the MRSN's actual financial results beat the analysts' financial forecasts?

Based on Mersana Therapeutics's last annual report (Dec 2023), the company's revenue was $36.86M, which missed the average analysts forecast of $51.27M by -28.12%. Apple's EBITDA was $-172M, beating the average prediction of $-71.399M by 140.44%. The company's net income was $-172M, beating the average estimation of $-155M by 10.96%. Apple's SG&A was $59.54M, missing the average forecast of $6.63B by -99.10%. Lastly, the company's EPS was $-1.48, beating the average prediction of $-1.382 by 7.06%. In terms of the last quarterly report (Dec 2023), Mersana Therapeutics's revenue was $10.7M, missing the average analysts' forecast of $14.74M by -27.40%. The company's EBITDA was $-18.998M, beating the average prediction of $-13.663M by 39.04%. Mersana Therapeutics's net income was $-18.561M, missing the average estimation of $-19.656M by -5.57%. The company's SG&A was $10.13M, missing the average forecast of $2.62B by -99.61%. Lastly, the company's EPS was $-0.13, missing the average prediction of $-0.16 by -18.84%